Radiotherapy Response Evaluation Using FDG PET-CT-established and Emerging Applications

Overview

Journal Br J Radiol

Publisher Oxford University Press

Specialty Radiology

Date 2016 Dec 24

PMID 28008773

Citations 9

Authors

Helen Cliffe

Chirag Patel

Robin Prestwich

Andrew Scarsbrook

Affiliations

Soon will be listed here.

Abstract

Radiation therapy is a common component of curative cancer treatment. However, there is a significant incidence of treatment failure. In these cases, salvage surgical options are sometimes appropriate. Accurate assessment of response and early recognition of treatment success or failure is therefore critical to guide treatment decisions and impacts on survival and the morbidity of treatment. Traditionally, treatment response has depended upon the anatomical measurement of disease. However, this may not correlate well with the presence of disease, especially after radiotherapy. Combined positron emission tomography (PET) and CT imaging employs radioactive tracers to identify molecular characteristics of tissues. PET imaging exploits the fact that malignancies have characteristic molecular profiles which differ compared with surrounding tissues. The complementary anatomical and functional information facilitates accurate non-invasive assessment of surrogate biomarkers of disease activity.

Citing Articles

Distribution of metastases after radiotherapy in relation to radiation exposure fields: evaluation by F-FDG PET/CT.

Liang J, Li W, Zhang R, Li W, Lin P, Nie H Sci Rep. 2024; 14(1):29816.

PMID: 39616185 PMC: 11608237. DOI: 10.1038/s41598-024-81303-3.

Clinical Utility of Second-Look FDG PET-CT to Stratify Incomplete Metabolic Response Post (Chemo) Radiotherapy in Oropharyngeal Squamous Cell Carcinoma.

Billingsley S, Iyizoba Z, Frood R, Vaidyanathan S, Prestwich R, Scarsbrook A Cancers (Basel). 2023; 15(2).

PMID: 36672413 PMC: 9856733. DOI: 10.3390/cancers15020464.

Combined PET-CT and MRI for response evaluation in patients with squamous cell anal carcinoma treated with curative-intent chemoradiotherapy.

Adusumilli P, Elsayed N, Theophanous S, Samuel R, Cooper R, Casanova N Eur Radiol. 2022; 32(8):5086-5096.

PMID: 35274187 PMC: 8913212. DOI: 10.1007/s00330-022-08648-z.

Qualitative and Quantitative Diagnosis in Head and Neck Cancer.

Lopez F, Makitie A, de Bree R, Franchi A, de Graaf P, Hernandez-Prera J Diagnostics (Basel). 2021; 11(9).

PMID: 34573868 PMC: 8466857. DOI: 10.3390/diagnostics11091526.

FDG positron emission tomography mining for metabolic imaging biomarkers of radiation-induced xerostomia in patients with oropharyngeal cancer.

Elhalawani H, Cardenas C, Volpe S, Barua S, Stieb S, Rock C Clin Transl Radiat Oncol. 2021; 29:93-101.

PMID: 34195391 PMC: 8239739. DOI: 10.1016/j.ctro.2021.05.011.

References

Henderson M, Hoopes D, Fletcher J, Lin P, Tann M, Yiannoutsos C . A pilot trial of serial 18F-fluorodeoxyglucose positron emission tomography in patients with medically inoperable stage I non-small-cell lung cancer treated with hypofractionated stereotactic body radiotherapy. Int J Radiat Oncol Biol Phys. 2009; 76(3):789-95. PMC: 2823932. DOI: 10.1016/j.ijrobp.2009.02.051. View

Yoon M, Ahn S, Nah B, Chung W, Song H, Yoo S . Metabolic response of lymph nodes immediately after RT is related with survival outcome of patients with pelvic node-positive cervical cancer using consecutive [18F]fluorodeoxyglucose-positron emission tomography/computed tomography. Int J Radiat Oncol Biol Phys. 2012; 84(4):e491-7. DOI: 10.1016/j.ijrobp.2012.05.041. View

Wu A, Goodman K . Clinical tools to predict outcomes in patients with esophageal cancer treated with definitive chemoradiation: are we there yet?. J Gastrointest Oncol. 2015; 6(1):53-9. PMC: 4294820. DOI: 10.3978/j.issn.2078-6891.2014.099. View

Barwick T, Taylor A, Rockall A . Functional imaging to predict tumor response in locally advanced cervical cancer. Curr Oncol Rep. 2013; 15(6):549-58. DOI: 10.1007/s11912-013-0344-2. View

Castadot P, Geets X, Lee J, Gregoire V . Adaptive functional image-guided IMRT in pharyngo-laryngeal squamous cell carcinoma: is the gain in dose distribution worth the effort?. Radiother Oncol. 2011; 101(3):343-50. DOI: 10.1016/j.radonc.2011.06.011. View

Joye I, Deroose C, Vandecaveye V, Haustermans K . The role of diffusion-weighted MRI and (18)F-FDG PET/CT in the prediction of pathologic complete response after radiochemotherapy for rectal cancer: a systematic review. Radiother Oncol. 2014; 113(2):158-65. DOI: 10.1016/j.radonc.2014.11.026. View

Vaupel P, Mayer A . Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev. 2007; 26(2):225-39. DOI: 10.1007/s10555-007-9055-1. View

Mak D, Hicks R, Rischin D, Solomon B, Peters L, Bressel M . Treatment response in the neck: p16+ versus p16- oropharyngeal cancer. J Med Imaging Radiat Oncol. 2013; 57(3):364-72. DOI: 10.1111/1754-9485.12024. View

Furuse K, Fukuoka M, Kawahara M, Nishikawa H, Takada Y, Kudoh S . Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol. 1999; 17(9):2692-9. DOI: 10.1200/JCO.1999.17.9.2692. View

10.

Saintigny P, Burger J . Recent advances in non-small cell lung cancer biology and clinical management. Discov Med. 2012; 13(71):287-97. View

11.

Kidd E, Thomas M, Siegel B, Dehdashti F, Grigsby P . Changes in cervical cancer FDG uptake during chemoradiation and association with response. Int J Radiat Oncol Biol Phys. 2012; 85(1):116-22. PMC: 3404156. DOI: 10.1016/j.ijrobp.2012.02.056. View

12.

Rinnab L, Simon J, Hautmann R, Cronauer M, Hohl K, Buck A . [(11)C]choline PET/CT in prostate cancer patients with biochemical recurrence after radical prostatectomy. World J Urol. 2009; 27(5):619-25. DOI: 10.1007/s00345-009-0371-7. View

13.

Gupta T, Master Z, Kannan S, Agarwal J, Ghsoh-Laskar S, Rangarajan V . Diagnostic performance of post-treatment FDG PET or FDG PET/CT imaging in head and neck cancer: a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging. 2011; 38(11):2083-95. DOI: 10.1007/s00259-011-1893-y. View

14.

Monjazeb A, Riedlinger G, Aklilu M, Geisinger K, Mishra G, Isom S . Outcomes of patients with esophageal cancer staged with [¹⁸F]fluorodeoxyglucose positron emission tomography (FDG-PET): can postchemoradiotherapy FDG-PET predict the utility of resection?. J Clin Oncol. 2010; 28(31):4714-21. PMC: 3020701. DOI: 10.1200/JCO.2010.30.7702. View

15.

Grigsby P, Siegel B, Dehdashti F, Rader J, Zoberi I . Posttherapy [18F] fluorodeoxyglucose positron emission tomography in carcinoma of the cervix: response and outcome. J Clin Oncol. 2004; 22(11):2167-71. DOI: 10.1200/JCO.2004.09.035. View

16.

Ding X, Li H, Wang Z, Huang W, Li B, Zang R . A clinical study of shrinking field radiation therapy based on (18)F-FDG PET/CT for stage III non-small cell lung cancer. Technol Cancer Res Treat. 2013; 12(3):251-7. DOI: 10.7785/tcrt.2012.500310. View

17.

Hofman M, Lau W, Hicks R . Somatostatin receptor imaging with 68Ga DOTATATE PET/CT: clinical utility, normal patterns, pearls, and pitfalls in interpretation. Radiographics. 2015; 35(2):500-16. DOI: 10.1148/rg.352140164. View

18.

Schwarz J, Siegel B, Dehdashti F, Grigsby P . Metabolic response on post-therapy FDG-PET predicts patterns of failure after radiotherapy for cervical cancer. Int J Radiat Oncol Biol Phys. 2011; 83(1):185-90. DOI: 10.1016/j.ijrobp.2011.05.053. View

19.

Kukar M, Alnaji R, Jabi F, Platz T, Attwood K, Nava H . Role of Repeat 18F-Fluorodeoxyglucose Positron Emission Tomography Examination in Predicting Pathologic Response Following Neoadjuvant Chemoradiotherapy for Esophageal Adenocarcinoma. JAMA Surg. 2015; 150(6):555-62. DOI: 10.1001/jamasurg.2014.3867. View

20.

Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun M . Cancer statistics, 2009. CA Cancer J Clin. 2009; 59(4):225-49. DOI: 10.3322/caac.20006. View